Dementia with Lewy bodies: Impact of co‐pathologies and implications for clinical trial design
Jon B. Toledo(Methodist Hospital), Michel J. Grothe(German Center for Neurodegenerative Diseases), Carla Abdelnour(Instituto de Salud Carlos III), Andrea Pilotto(Fondazione Europea Ricerca Biomedica), Daniel Ferreira(Universidad Fernando Pessoa Canarias), Joseph Kane(University of Ulster), Sonja W. Scholz(Johns Hopkins University), Dag Aarsland(King's College London), James B. Leverenz(University of Washington), Federico Rodríguez‐Porcel(Medical University of South Carolina), Bradley F. Boeve(Mayo Clinic in Arizona), Kathryn A Wyman‐Chick(HealthPartners), Angela Taylor(Research Network (United States)), Rimona S. Weil(University College London), Arvid Rongve(Privatsykehuset Haugesund), Simon J.G. Lewis(The University of Sydney), Iracema Leroi(Trinity College Dublin), Ian G. McKeith(Newcastle Hospitals - Campus for Ageing and Vitality), John‐Paul Taylor(School of the Art Institute of Chicago)
Cited by 99
Related Papers
Diagnosis and management of dementia with Lewy bodies
|Neurology|2017|4.4k
New insights into the genetic etiology of Alzheimer’s disease and related dementias
|Nature Genetics|2022|2.5k
Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk
|Nature Genetics|2019|2.5k
Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17
|Nature|2006|2.1k
Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature
|Journal of Neuropathology & Experimental Neurology|2012|2.1k